The need for the creation of new antibiotics has never been more urgent with the growing trend of antibiotic resistance in the bacterial world. Bacteria can become resistant because of random mutations that can give rise to degradation enzymes that will interfere with the transport mechanisms. To make the issues worse, bacteria confer resistance. Antibiotic resistance has cost the economy $168 million in 2018 and caused more than 2 million infections. Pharmaceutical companies have decreased the amount of time and money spent searching for antibiotics due to the lack of revenue from antibiotics. The USFDA approval of new drugs decreased by 56% between 1998-2002. This research focuses on the production of new antibiotics and exploring the metabolic profiles of the antibiotic producers with a long-term goal to share the pilot-scale information with industries. Currently, 3 Bacillus sp. isolated from the soil have shown to inhibit the growth of Acinetobacter baylyi and Enterococcus raffinosus. To accomplish the discovery of new antibiotic compounds, co-culturing will be utilized with the hopes of revealing cryptic genes that would otherwise be silenced in pure culture. Preliminary results from co-culturing revealed that the isolates can eliminate the pathogens from a mixed culture. Additionally, it was discovered that our Bacillus isolates utilize a broad spectrum of carbon sources. During metabolic profiling, it was discovered that 2-hydroxybenzoic acid was not utilized efficiently. This result is significant as 2-hydroxybenzoic acid is an important precursor compound to many other compounds and it may promote antibiotic production from the Bacillus sp. Future research will be focused on genomic analysis to examine the antibiotic biosynthetic islands within the genome. The genes will be tested for expression using qRT-PCR when co-cultured with the pathogen. Various biochemical tests will also be performed with the hopes of obtaining a concrete metabolic profile.